| 臺大學術典藏 |
2020-09-28T08:03:31Z |
Influence of patient and provider factors on the workload of on-call physicians A general internal medicine cohort observational study
|
Yu C.-J.; Ko W.-J.; Chang R.-E.; Hsu N.-C.; Huang C.-C.; JIH-SHUIN JERNG; Hsu C.-H.; Yang M.-C. |
| 臺大學術典藏 |
2020-09-23T06:22:46Z |
Tc-99m MIBI SPECT in detecting metastatic papillary thyroid carcinoma in patients with elevated human serum thyroglobulin levels but negative I-131 whole body scan
|
Hsu C.-H.;Liu F.-Y.;Ruoh-Fang Yen;Kao C.-H.; Hsu C.-H.; Liu F.-Y.; RUOH-FANG YEN; Kao C.-H. |
| 臺大學術典藏 |
2020-09-23T06:22:30Z |
Comparative study between endoscopic ultrasonography and positron emission tomography-computed tomography in staging patients with esophageal squamous cell carcinoma
|
Yen T.-J.; Chung C.-S.; Wu Y.-W.; RUOH-FANG YEN; Cheng M.-F.; Lee J.-M.; Hsu C.-H.; Chang Y.-L.; Wang H.-P. |
| 臺大學術典藏 |
2020-09-22T09:06:05Z |
Relationship of Neonatal Cerebral Blood Flow Velocity Asymmetry with Early Motor, Cognitive and Language Development in Term Infants
|
Chen C.-Y.; STEVEN SHINN-FORNG PENG; Hung H.-Y.; Chang J.-H.; Chen W.J.; Jeng S.-F.; Chou H.-C.; Chiu N.-C.; Hsu C.-H.; Hsieh W.-S.; Wu Y.-C. |
| 臺大學術典藏 |
2020-09-22T09:06:00Z |
Neonatal respiratory status predicts longitudinal respiratory health outcomes in preterm infants
|
Wang L.-Y.; Chen P.-S.; Hsieh W.-S.; Hsu C.-H.; STEVEN SHINN-FORNG PENG; Jeng S.-F.; Luo H.-J. |
| 臺大學術典藏 |
2020-09-22T08:51:45Z |
Relationship of Neonatal Cerebral Blood Flow Velocity Asymmetry with Early Motor, Cognitive and Language Development in Term Infants
|
Jeng S.-F.; Chen W.J.; Chang J.-H.; Hung H.-Y.; Peng S.-F.; Chen C.-Y.; Chou H.-C.; Chiu N.-C.; Hsu C.-H.; Wu Y.-C.; Hsieh W.-S. |
| 臺大學術典藏 |
2020-09-22T08:51:41Z |
Neonatal respiratory status predicts longitudinal respiratory health outcomes in preterm infants
|
Luo H.-J.; Wang L.-Y.; Chen P.-S.; Hsieh W.-S.; Hsu C.-H.; Peng S.; Jeng S.-F. |
| 臺大學術典藏 |
2020-09-22T07:39:54Z |
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil
|
Chao-Yu Hsu ;Shen Y.-C. ;Yu C.-W. ;Hsu C. ;Hu F.-C. ;Hsu C.-H. ;Chen B.-B. ;Wei S.-Y. ;Cheng A.-L. ;Shih T.T.-F.; CHAO-YU HSU; Shen Y.-C.; Yu C.-W.; Hsu C.; Hu F.-C.; Hsu C.-H.; Chen B.-B.; Wei S.-Y.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2020-09-22T07:39:51Z |
Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma: Comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy
|
Shih T.T.-F.; Cheng A.-L.; Hsu C.-H.; Hsu C.; Liang P.-C.; Chen B.-B.; CHAO-YU HSU; Yu C.-W. |
| 臺大學術典藏 |
2020-09-22T07:39:50Z |
Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma
|
Chen B.-B.;Chao-Yu Hsu;Yu C.-W.;Liang P.-C.;Hsu C.;Hsu C.-H.;Cheng A.-L.;Shih T.T.-F.; Chen B.-B.; CHAO-YU HSU; Yu C.-W.; Liang P.-C.; Hsu C.; Hsu C.-H.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2020-09-15T05:23:51Z |
Prescription patterns of anti-diabetic medications and clinical outcomes in Asian patients with heart failure and diabetes mellitus
|
Loh S.Y.; Reyes E.; Ching M.E.; Khoo D.Z.L.; Yew M.S.; Huang W.; Leong K.T.G.; See J.H.J.; Lim Y.B.; Tan S.; Yeo C.; Chai S.C.; Siswanto B.B.; Jaufeerally F.R.; KUO-LIONG CHIEN; Lee E.M.; Yeo P.S.D.; Poh K.K.; Chai P.; Wong C.C.R.; Santos J.; Yew K.L.; Narasimhan C.; Zhudi A.S.B.M.; Sari N.A.M.; Sridhar G.S.; Zuhdi A.S.M.; Ismail M.D.; Ong T.K.; Cham Y.L.; Khiew N.Z.; Said A.B.; Fong A.Y.Y.; Ngarmukos T.; Amin N.H.M.; Seng K.C.; Tan S.K.; Chan L.L.H.; Teo L.L.Y.; Lapitan R.; Andal R.; Lopez E.; Sim K.L.D.; Park S.W.; Tan B.Y.; Lim C.P.; Lim A.; Noda T.; Nakajima I.; Lam C.S.P.; Wada M.; Ishibashi K.; Kurita T.; Yasuoka R.; Asai K.; Murai K.; Kubota Y.; Izumi Y.; Ikeda T.; Hisatake S.; Uhm J.-S.; Kabuki T.; Kiuchi S.; Abidin I.Z.; Azmee M.G.; Omar R.; Ghazi A.M.; Khelae S.K.; Chew D.S.P.; Yap L.B.; Hussin A.; Muhammad Z.; Wong C.K.; Liew H.B.; Arbain A.N.; Tan Y.Z.; Mojolou R.A.; Asnawi M.H.M.; Augustine A.-A.; Naik A.; Kaur D.; Sridevi C.; Raghu K.; Gopi A.; Sastry B.K.S.; Yu C.M.; Jin Q.; Ling T.; Li X.; Seo H.S.; Zhou F.; Zhou Y.; Xu D.; Zhang H.; Su Y.; Chen X.; Qin S.; Wang J.; Gong X.; Wu Z.; Oh D.J.; Surarso R.; Danny S.S.; Martanto E.; Joung B.; Erwinanto, Munawar M.; Pambudi J.A.; Lukito A.; Pardede I.; Thengker A.; Damay V.; Tedjokusumo P.; Purayil M.P.; Sharma M.K.; Sawhney J.; Mittal S.; Verma R.; Sethi H.J.S.; Kumar M.; Chopra V.; Kim E.J.; Tandon R.; Parikh K.; Chandarana A.; Shah U.; Park C.G.; Chag M.; Baxi H.; Gupta S.; Bhatia J.; Khakhkhar V.; Sankhla V.; Patel T.; Kapoor V.; Wander G.S.; Othman M.K.; Lee Y.W.; Yen C.H.; Hagiwara N.; Suzuki A.; Suzuki T.; Hong S.K.; Lee S.; Soo L.D.; Kim D.-H.; Shim J.; Lee M.H.; Park S.-M.; Roh S.-Y.; Cho I.-J.; Park H.-N.; Park H.-W.; Cho J.-G.; Yoon N.; Lee K.; Kim K.H.; Kim S.H.; Hung C.-L.; Saharudin S.; Beh B.C.; Laothavorn P.; Tiyanon W.; Wongcharoen W.; Wu L.; Phrommintikul A.; on behalf of the ASIAN-HF Investigators; Xie Y.; Rha S.W.; Chandavimol M.; Yingchoncharoen T.; Hsieh L.-C.; Hsu C.-H.; Lo P.-H.; Chen K.-W.; Hsiao L.-C.; Wang Y.-C.; Na J.O.; Lu C.-R.; Wu H.-P.; Chen K.; Lin Y.-N.; Chang S.-S.; Liang H.-Y.; Wu C.-H.; Lo L.-W.; Huang P.-H.; Chang S.-L.; Fan X.; Lin Y.-J.; Choi J.-I.; Leu H.-B.; Wang K.-L.; Sung S.-H.; Chao T.-F.; Yu W.-C.; Hsu C.-N.; Lin J.-W.; Kuo J.-Y.; Yen C.-H.; Hwang J.-J.; Shimizu W.; Kim Y.H.; KUO-LIONG CHIEN; Su T.-C.; Lin L.-Y.; Juang J.-M.; Lin Y.-H.; Chiang F.-T.; Lin J.-L.; Ho Y.-L.; Lee C.-M.; Lin P.-C.; Kim M.; Zhang S.; Hung C.-S.; Chang S.-N.; Chia Y.M.F.; Teng T.-H.K.; Tay W.T.; Anand I.; MacDonald M.R.; Yap J.; Chandramouli C.; Richards A.M.; Tromp J.; Ouwerkerk W.; Ling L.H.; Tulsidas H.; Aung T.; Ong H.Y.; Ling L.F.; Soon D.K.N.; Yeh H.-I. |
| 臺大學術典藏 |
2020-08-14T03:15:30Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu L.-C.; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; I-LUN SHIH; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-08-12T06:35:40Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Lin Z.-Z.;Hsu C.;Chang Y.-C.;Chong-Jen Yu;Hsu C.-H.;Lin C.-C.;Cheng A.-L.;Yang P.-C.;Yang C.-H.; Lin Z.-Z.; Hsu C.; Chang Y.-C.; CHONG-JEN YU; Hsu C.-H.; Lin C.-C.; Cheng A.-L.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2020-08-12T02:42:39Z |
Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma
|
Bang-Bin Chen;Hsu C.-Y.;Yu C.-W.;Liang P.-C.;Hsu C.;Hsu C.-H.;Cheng A.-L.;Shih T.T.-F.; BANG-BIN CHEN; Hsu C.-Y.; Yu C.-W.; Liang P.-C.; Hsu C.; Hsu C.-H.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2020-08-12T02:42:37Z |
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
|
Chao Y.; Hsu C.; Lee R.-C.; Lin Z.-Z.; BANG-BIN CHEN; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; Hsu C.-H.; Cheng A.-L.; Lin Z.-Z.;Bang-Bin Chen;Hung Y.-P.;Huang P.-H.;Shen Y.-C.;Shao Y.-Y.;Hsu C.-H.;Cheng A.-L.;Lee R.-C.;Chao Y.;Hsu C. |
| 臺大學術典藏 |
2020-08-11T08:36:51Z |
A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy
|
Shao Y.-Y.; PO-CHIN LIANG; Wu Y.-M.; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Hsu C.; Cheng A.-L.; Lin Z.-Z. |
| 臺大學術典藏 |
2020-08-11T08:36:45Z |
Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma: Comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy
|
Chen B.-B.; Hsu C.-Y.; Yu C.-W.; PO-CHIN LIANG; Hsu C.; Hsu C.-H.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2020-08-07T02:32:18Z |
Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy
|
Shao Y.-Y.; CHIH-HORNG WU; Lu L.-C.; Chan S.-Y.; Ma Y.-Y.; Yen F.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-08-06T07:51:46Z |
Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma: Comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy
|
Chen B.-B.; Hsu C.-Y.; Yu C.-W.; Liang P.-C.; Hsu C.; Hsu C.-H.; Cheng A.-L.; TIFFANY TING-FANG SHIH |
| 臺大學術典藏 |
2020-08-06T07:51:44Z |
Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma
|
Yu C.-W.; Liang P.-C.; Hsu C.; Hsu C.-H.; Cheng A.-L.; TIFFANY TING-FANG SHIH; Hsu C.-Y.; Chen B.-B. |
| 臺大學術典藏 |
2020-07-10T08:16:36Z |
Brief report: Taiwanese infants' mental and motor development - 6-24 Months
|
Wu, Y.-T.; Tsou, K.-I.; Hsu, C.-H.; Fang, L.-J.; Yao, G.; Jeng, S.-F.; KAI-PING GRACE YAO; Wu, Y.-T.; Tsou, K.-I.; Hsu, C.-H.; Fang, L.-J.; Yao, G.; Jeng, S.-F. |
| 臺大學術典藏 |
2020-07-09T02:57:04Z |
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil
|
Hsu C.-H.; Chen B.-B.; Wei S.-Y.; Cheng A.-L.; Shih T.T.-F.; Hsu C.-Y. ;Shen Y.-C. ;Chih-Wei Yu ;Hsu C. ;Hu F.-C. ;Hsu C.-H. ;Chen B.-B. ;Wei S.-Y. ;Cheng A.-L. ;Shih T.T.-F.; Hsu C.-Y.; Shen Y.-C.; CHIH-WEI YU; Hsu C.; Hu F.-C. |
| 臺大學術典藏 |
2020-07-09T02:57:02Z |
Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma: Comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy
|
Chen B.-B.; Hsu C.-Y.; CHIH-WEI YU; Liang P.-C.; Hsu C.; Hsu C.-H.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2020-07-09T02:57:01Z |
Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma
|
Chen B.-B.;Hsu C.-Y.;Chih-Wei Yu;Liang P.-C.;Hsu C.;Hsu C.-H.;Cheng A.-L.;Shih T.T.-F.; Chen B.-B.; Hsu C.-Y.; CHIH-WEI YU; Liang P.-C.; Hsu C.; Hsu C.-H.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2020-07-03T08:45:42Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y;Chen B.-B;Da-Liang Ou;Lin Z.-Z;Hsu C.-H;Wang M.-J;Cheng A.-L;Hsu C.; Shao Y.-Y; Chen B.-B; DA-LIANG OU; Lin Z.-Z; Hsu C.-H; Wang M.-J; Cheng A.-L; Hsu C. |
